Lupa

Search the repository Help

A- | A+ | Print
Query: search in
search in
search in
search in
* old and bolonia study programme

Options:
  Reset


1 - 5 / 5
First pagePrevious page1Next pageLast page
1.
2.
3.
Enhanced cytotoxicity of bleomycin and cysplatin after electroporation in murine colorcetal carcinoma cells
Maja Čemažar, Vesna Todorović, Karel Flisar, Gregor Serša, 2009, original scientific article

Found in: osebi
Published: 10.07.2015; Views: 1365; Downloads: 4
URL Full text (0,00 KB)

4.
Endoglin (CD105) silencing mediated by shRNA under the control of Endothelin-1 promoter for targeted gene therapy of Melanoma
Simona Kranjc, Boris Turk, Nataša Tešić, Maja Čemažar, Véronique Préat, Gregor Serša, Urška Kamenšek, Monika Štimac, Urša Lampreht Tratar, Gaëlle Vandermeulen, Miha Butinar, 2015, original scientific article

Abstract: Endoglin (CD105), a transforming growth factor (TGF)-% coreceptor, and endothelin-1, a vasoconstrictor peptide, are both overexpressed in tumor endothelial and melanoma cells. Their targeting is therefore a promising therapeutic approach for melanoma tumors. The aim of our study was to construct a eukaryotic expression plasmid encoding the shRNA molecules against CD105 under the control of endothelin-1 promoter and to evaluate its therapeutic potential both in vitro in murine B16F10-luc melanoma and SVEC4-10 endothelial cells and in vivo in mice bearing highly metastatic B16F10-luc tumors. Plasmid encoding shRNA against CD105 under the control of the constitutive U6 promoter was used as a control. We demonstrated the antiproliferative and antiangiogenic effects of both plasmids in SVEC4-10 cells, as well as a moderate antitumor and pronounced antimetastatic effect in B16F10-luc tumors in vivo. Our results provide evidence that targeting melanoma with shRNA molecules against CD105 under the control of endothelin-1 promoter is a feasible and effective treatment, especially for the reduction of metastatic spread.
Found in: osebi
Keywords: melanoma, electroporation, endoglin (CD105), endothelin-1, gene therapy
Published: 14.10.2015; Views: 1699; Downloads: 72
URL Full text (0,00 KB)

5.
Adjuvant TNF-a therapy to electrochemotherapy with intravenous cisplatin in murine sarcoma exerts synergistic antitumor effectiveness
Maja Čemažar, Andrej Cör, Vesna Todorović, Janez Ščančar, Simona Kranjc, Gregor Serša, Urška Kamenšek, Monika Štimac, Urša Lampreht Tratar, 2015, original scientific article

Abstract: Background. Electrochemotherapy is a tumour ablation modality, based on electroporation of the cell membrane, allowing non-permeant anticancer drugs to enter the cell, thus augmenting their cytotoxicity by orders of magnitude. In preclinical studies, bleomycin and cisplatin proved to be the most suitable for clinical use. Intravenous administration of cisplatin for electrochemotherapy is still not widely accepted in the clinics, presumably due to its lower antitumor effectiveness, but adjuvant therapy by immunomodulatory or vascular-targeting agents could provide a way for its potentiation. Hence, the aim of the present study was to explore the possibility of adjuvant tumour necrosis factor % (TNF-%) therapy to potentiate antitumor effectiveness of electrochemotherapy with intravenous cisplatin administration in murine sarcoma. Materials and methods. In vivo study was designed to evaluate the effect of TNF-% applied before or after the electrochemotherapy and to evaluate the effect of adjuvant TNF-% on electrochemotherapy with different cisplatin doses. Results. A synergistic interaction between TNF-% and electrochemotherapy was observed. Administration of TNF-% before the electrochemotherapy resulted in longer tumour growth delay and increased tumour curability, and was significantly more effective than TNF-% administration after the electrochemotherapy. Tumour analysis revealed increased platinum content in tumours, TNF-% induced blood vessel damage and increased tumour necrosis after combination of TNF-% and electrochemotherapy, indicating an anti-vascular action of TNF-%. In addition, immunomodulatory effect might have contributed to curability rate of the tumours. Conclusion. Adjuvant intratumoural TNF-% therapy synergistically contributes to electrochemotherapy with intravenous cisplatin administration. Due to its potentiation at all doses of cisplatin, the combined treatment is predicted to be effective also in tumours, where the drug concentration is suboptimal or in bigger tumours, where electrochemotherapy with intravenous cisplatin is not expected to be sufficiently effective.
Found in: osebi
Keywords: electrochemotherapy, TNF, adjuvant immunotherapy, cisplatin
Published: 09.08.2016; Views: 2398; Downloads: 77
URL Full text (0,00 KB)

Search done in 0 sec.
Back to top
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica